15 completed, 1 recruiting, 1 terminated, 1 unknown. 7 Phase 3, 6 Phase 2, 4 Phase 4, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 6, Withdrawn 1 |
| Phase 2 | 6 | Completed 6 |
| Phase 4 | 4 | Completed 3, Terminated 1 |
| Phase 1 | 3 | Completed 3 |
Follow AZD1222: new trials by email Literature Review of AZD1222 trials Research Report on AZD1222
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above MVC-COV1901, AZD1222 - COVID-19 Vaccine | Phase 3 | Completed | Medigen Vaccine Biologics Corp. | 250 | 2022-07-30 | 2023-10-23 |
| A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Vaccine Compared With AZD1222 MVC-COV1901, AZD1222 - COVID-19 Vaccine | Phase 3 | Completed | Medigen Vaccine Biologics Corp. | 200 | 2022-07-09 | 2023-10-23 |
| Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing Trial Sinovac, AZD1222, BNT162b2 - COVID-19 | Phase 4 | Completed | Albert B. Sabin Vaccine Institute | 2354 | 2022-07-05 | 2024-01-30 |
| EU Secondary Data Post-Authorisation Safety Study of AZD1222 AZD1222 - COVID-19, Vaccine Adverse Events of Special Interest | Completed | AstraZeneca | 5321930 | 2022-02-18 | 2025-01-28 | |
| A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults AZD1222 - COVID-19, SARS-CoV-2 | Phase 4 | Terminated | AstraZeneca | 34 | 2022-01-31 | 2025-01-27 |
| A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19 Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222 - COVID-19 Vaccine | Phase 2 | Completed | Medigen Vaccine Biologics Corp. | 804 | 2022-01-22 | 2023-03-15 |
| A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults MVC-COV1901, AZD1222 - Covid19 Vaccine | Phase 3 | Completed | Medigen Vaccine Biologics Corp. | 1030 | 2021-10-08 | 2022-09-30 |
| Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19 AZD1222, rAd26-S - COVID-19 | Phase 1 / Phase 2 | Completed | R-Pharm | 100 | 2021-09-15 | 2022-06-03 |
| Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death AZD1222 - COVID-19, Pneumonia, Viral | Phase 4 | Completed | Shabir Madhi | 75012 | 2021-08-30 | 2023-08-29 |
| Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19) AZD1222, rAd26-S - COVID-19 | Phase 1 / Phase 2 | Completed | R-Pharm | 100 | 2021-07-13 | 2022-10-26 |
| Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults AZD1222, AZD2816 - COVID-19, SARS-CoV-2 | Phase 2 / Phase 3 | Completed | AstraZeneca | 2843 | 2021-06-27 | 2024-09-19 |
| Antibody Response to COVID-19 Vaccines in Liver Disease Patients BNT162b2, CoronaVac, AZD1222 - Chronic Liver Disease | Phase 4 | Completed | Humanity & Health Medical Group Limited | 232 | 2021-05-21 | 2023-10-04 |
| COV-COMPARE Immunogenicity of Vaccine VLA2001 Compared to AZD1222 VLA2001, AZD1222, VLA2001 - adolescent part - SARS-CoV-2 Virus Infection | Phase 3 | Completed | Valneva Austria GmbH | 4034 | 2021-04-26 | 2023-03-20 |
| COVID-19 Vaccines Safety Tracking (CoVaST) BNT162b2, mRNA-1273, AZD1222 - Adverse Reaction to Vaccine, COVID19 Vaccine | Recruiting | Masaryk University | 30000 | 2021-04-01 | 2022-04-06 | |
| Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention AZD1222, rAd26-S - COVID-19 | Phase 2 | Completed | R-Pharm | 100 | 2021-03-05 | 2022-06-03 |
| The COVID-19 Back-to-Normal Study: Analysis of Multiple Outcomes COVID-19 vaccines - COVID-19 Vaccines | Unknown | Mebo Research, Inc. | 2000 | 2021-01-05 | 2024-01-26 | |
| AZD1222 Vaccine for the Prevention of COVID-19 AZD1222 - COVID-19 | Phase 3 | Withdrawn | AstraZeneca | 2020-09-02 | 2021-10-01 | |
| Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults AZD1222, Placebo - COVID-19, SARS-CoV-2 | Phase 3 | Completed | AstraZeneca | 32450 | 2020-08-28 | 2024-02-05 |
| Study of AZD1222 for the Prevention of COVID-19 in Japan AZD1222, 0.9% (w/v) saline - COVID-19 | Phase 1 / Phase 2 | Completed | AstraZeneca | 256 | 2020-08-23 | 2024-03-01 |
COVID-19 (14) · Coronavirus Infections (2) · Lung Diseases (2) · Respiration Disorders (2) · Drug-Related Side Effects and Adverse Reactions (1) · Long Term Adverse Effects (1) · Pneumonia (1) · Pneumonia, Viral (1)
AstraZeneca (6) · Medigen Vaccine Biologics Corp. (4) · R-Pharm (3) · Albert B. Sabin Vaccine Institute (1) · Humanity & Health Medical Group Limited (1) · Masaryk University (1) · Mebo Research, Inc. (1) · Shabir Madhi (1) · Valneva Austria GmbH (1)
United Kingdom (4) · Russia (3) · United States (3) · Brazil (2) · Paraguay (2) · Poland (2) · Thailand (2) · Azerbaijan (1) · Canada (1) · Chile (1) · Croatia (1) · Czechia (1) · Estonia (1) · Eswatini (1) · Ethiopia (1)
Mikhail Samsonov (3) · Allen Lien, MD. Dr.PH (2) · Allen Lien, MD. DrPH (1) · Ann Falsey, MD (1) · Cristina Rebordosa, MD, PhD (1) · Irene Gabashvili, PhD (1) · Luis Francisco Armoa Garcia, MD.Ph.D. (1) · Magda Sobieszczyk, MD (1)
PMID 34360156, PMID 34587382, PMID 34688944, PMID 36075233, PMID 36106642, PMID 36309347, PMID 36610390, PMID 36713413, PMID 37080829, PMID 37271703, PMID 37385888, PMID 37406777, PMID 37783221, PMID 38643547, PMID 38827749, PMID 38878794, PMID 39225478, PMID 40620571